EC slaps Teva with ā¬463M fine over misuse of Copaxone patents
The European Commission (EC) fined Teva Pharmaceuticals ā¬462.6 million ā more that $502 million ā after an investigation it launched found the company illegally tried to stop competitor versions of Copaxone (glatiramer acetate injection), its blockbuster drug for multiple sclerosis (MS), from entering markets. Several patents…